Edward Broenniman Net Worth

Edward Broenniman biography

Edward G. Broenniman serves as Chairman of the Board of the Company. Mr. Broenniman has served as a director of the Company since March 1999. He has been the managing director of The Piedmont Group, LLC, a venture advisory firm, since 1978. Mr. Broenniman recently served on the Board of Directors of publicly traded QuesTech (acquired by CACI International), and currently serves on the Boards of two privately held firms. He serves on the Boards of the nonprofit entities, the Dingman Center for Entrepreneurship’s Board of Advisors at the University of Maryland, the National Association of Corporate Directors, National Capital Chapter (Founder, Chair from 2003 to 2005 and director from 2001 to 2014) and the Board of the Association for Corporate Growth, National Capital Chapter. Mr. Broenniman received his MBA from Stanford Graduate School of Business and his BA from Yale University.

How old is Edward Broenniman?

Edward Broenniman is 84, he's been the Chairman of the Board of Aethlon Medical Inc since 2020. There are no older and 9 younger executives at Aethlon Medical Inc.

What's Edward Broenniman's mailing address?

Edward's mailing address filed with the SEC is 11555 SORRENTO VALLEY ROAD, SUITE 203, , SAN DIEGO, CA, 92121.

Insiders trading at Aethlon Medical Inc

Over the last 11 years, insiders at Aethlon Medical Inc have traded over 56,658$ worth of Aethlon Medical Inc stock. The most active insiders traders include James A Joyce、Angela Rossetti、Chetan Shah. On average, Aethlon Medical Inc executives and independent directors trade stock every 56 days with the average trade being worth of 4,427$. The most recent stock trade was executed by Chetan Shah on 17 December 2020, trading 26,852 units of AEMD stock currently worth 56,658$.

What does Aethlon Medical Inc do?

the aethlon medical (nasdaq:aemd) mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. our aethlon adapt™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. the aethlon adapt™ product pipeline includes the hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as hiv and hepatitis c.

Aethlon Medical Inc executives and stock owners

Aethlon Medical Inc executives and other stock owners filed with the SEC include:

• Steven P. Larosa M.D.,
  Chief Medical Officer & Acting Chief Scientific Officer
• Dr. Charles J. Fisher Jr., M.D.,
  CEO, Director & Member of Extracorporeal Therapy Advisory Board
• James B. Frakes M.B.A.,
  CFO, Sr. VP of Fin. & Sec.
• James Frakes,
  Chief Financial Officer, Senior Vice President - Finance, Secretary
• Charles Fisher,
  Chief Executive Officer
• Guy F. Cipriani BS (Eng.), MBA,
  Sr. VP, Chief Bus. Officer & Director
• Chetan Shah,
  Independent Director
• Sabrina Johnson,
  Independent Director
• Guy Cipriani,
  Independent Director
• Edward Broenniman,
  Chairman of the Board
• Dr. Richard H. Tullis,
  Consultant
• Sunil Sawhney,
  Head of Clinical Studies
• Rodney S Kenley,
  President
• Timothy C Jr Rodell,
  Chief Executive Officer
• Franklyn S Jr Barry,
  Director
• Richard Tullis,
  VP, CHIEF SCIENCE OFFICER
• Phillip A Ward,
  Director
• James A Joyce,
  Chairman, CEO, Secretary
• Nicolas Gikakis,
  
• Steven P Larosa,
  Chief Medical Officer
• Angela Rossetti,
  
• Lee D Arnold,
  Chief Scientific Officer